
Clinical trials due to COVID-19 read out March 2020 worldwide, by stage
As of March 24, 2020, there were 315 pivotal trials of unapproved, novel drugs that are approaching readout during 2020. These studies are at risk of being compromised due to the coronavirus (Covid-19) pandemic, costing pharmaceutical companies both time and money. There were 147 active trials at risk, with an estimated cost of nearly 12 billion U.S. dollars.